688428 诺诚健华
已收盘 07-31 15:00:01
资讯
新帖
简况
7月30日诺诚健华跌5.72%，富国精准医疗混合A基金重仓该股
证券之星 · 07-30 16:42
7月30日诺诚健华跌5.72%，富国精准医疗混合A基金重仓该股
诺诚健华Tyk2抑制剂Fadeucravacitinib (Icp-488)在银屑病三期研究中达成主要终点
美股速递 · 07-27
诺诚健华Tyk2抑制剂Fadeucravacitinib (Icp-488)在银屑病三期研究中达成主要终点
诺诚健华：Fadeucravacitinib (Icp-488) 治疗中重度斑块状银屑病 III 期注册试验成功达成主要终点
美股速递 · 07-27
诺诚健华：Fadeucravacitinib (Icp-488) 治疗中重度斑块状银屑病 III 期注册试验成功达成主要终点
诺诚健华：ICP-488治疗银屑病III期试验达主要终点
南方财经网 · 07-27
诺诚健华：ICP-488治疗银屑病III期试验达主要终点
BMS的留白，诺诚健华的窗口
蓝鲸财经 · 07-22
BMS的留白，诺诚健华的窗口
每周股票复盘：诺诚健华（688428）Soficitinib治疗特应性皮炎Ⅲ期达主要终点
证券之星 · 07-19
每周股票复盘：诺诚健华（688428）Soficitinib治疗特应性皮炎Ⅲ期达主要终点
7月17日诺诚健华跌9.21%，富国精准医疗混合A基金重仓该股
证券之星 · 07-17
7月17日诺诚健华跌9.21%，富国精准医疗混合A基金重仓该股
诺诚健华-索法西替尼二期试验展现良好安全性，未出现新的安全信号
美股速递 · 07-16
诺诚健华-索法西替尼二期试验展现良好安全性，未出现新的安全信号
诺诚健华旗下Soficitinib在II期试验中较安慰剂展现统计学显著改善
美股速递 · 07-16
诺诚健华旗下Soficitinib在II期试验中较安慰剂展现统计学显著改善
诺诚健华TYK2抑制剂索法西替尼治疗白癜风II期研究达主要终点
美股速递 · 07-16
诺诚健华TYK2抑制剂索法西替尼治疗白癜风II期研究达主要终点
诺诚健华(688428.SH)：Soficitinib(ICP-332)治疗非节段型白癜风Ⅱ期研究达到主要终点
智通财经 · 07-16
诺诚健华(688428.SH)：Soficitinib(ICP-332)治疗非节段型白癜风Ⅱ期研究达到主要终点
诺诚健华（688428）披露2023年人民币股份激励计划归属结果，7月15日股价下跌2.18%
证券之星 · 07-15
诺诚健华（688428）披露2023年人民币股份激励计划归属结果，7月15日股价下跌2.18%
诺诚健华-奥布替尼达到统计学显著主要终点及多个次要终点
美股速递 · 07-15
诺诚健华-奥布替尼达到统计学显著主要终点及多个次要终点
诺诚健华宣布TYK2抑制剂Soficitinib治疗特应性皮炎III期研究达到主要终点
美股速递 · 07-15
诺诚健华宣布TYK2抑制剂Soficitinib治疗特应性皮炎III期研究达到主要终点
诺诚健华(09969)：soficitinib (ICP-332)治疗中重度特应性皮炎的 III期注册性试验成功达到其主要终点
智通财经 · 07-15
诺诚健华(09969)：soficitinib (ICP-332)治疗中重度特应性皮炎的 III期注册性试验成功达到其主要终点
诺诚健华：Soficitinib治疗中重度特应性皮炎Ⅲ期临床试验达主要终点
格隆汇 · 07-15
诺诚健华：Soficitinib治疗中重度特应性皮炎Ⅲ期临床试验达主要终点
每周股票复盘：诺诚健华（688428）科创板股份归属上市
证券之星 · 07-12
每周股票复盘：诺诚健华（688428）科创板股份归属上市
诺诚健华（688428）披露2023年科创板限制性股票激励计划归属结果暨股份上市公告，7月10日股价上涨2.34%
证券之星 · 07-10
诺诚健华（688428）披露2023年科创板限制性股票激励计划归属结果暨股份上市公告，7月10日股价上涨2.34%
港股创新药概念股盘中拉升，荣昌生物、诺诚健华涨超5%
老虎资讯综合 · 07-10
港股创新药概念股盘中拉升，荣昌生物、诺诚健华涨超5%
诺诚健华：截止到2026年6月30日公司A股股东户数约为2万户
证券之星 · 07-07
诺诚健华：截止到2026年6月30日公司A股股东户数约为2万户
加载更多
公司概况
公司名称：
诺诚健华医药有限公司
所属行业：
医药制造业
上市日期：
2022-09-21
主营业务：
诺诚健华医药有限公司的主营业务是创新药的研发、生产及商业化。公司的主要产品是奥布替尼。
发行价格：
11.03
{"stockData":{"symbol":"688428","market":"SH","secType":"STK","nameCN":"诺诚健华","latestPrice":26.46,"timestamp":1785481201000,"preClose":25.86,"halted":0,"volume":8606885,"delay":0,"changeRate":0.0232,"floatShares":273000000,"shares":1769000000,"eps":0.4129,"marketStatus":"已收盘","change":0.6,"latestTime":"07-31 15:00:01","open":26.06,"high":26.9,"low":26,"amount":229000000,"amplitude":0.0348,"askPrice":26.47,"askSize":3,"bidPrice":26.46,"bidSize":225,"shortable":0,"etf":0,"ttmEps":0.4129,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1785720600000},"marketStatusCode":5,"adr":0,"adjPreClose":25.86,"symbolType":"stock_kcb","openAndCloseTimeList":[[1785461400000,1785468600000],[1785474000000,1785481200000]],"highLimit":28.45,"lowLimit":23.27,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1769107002,"isCdr":false,"pbRate":6.37,"roa":"--","peRate":64.083313,"roe":"1.4%","epsLYR":0.38,"committee":-0.094891,"marketValue":46811000000,"turnoverRate":0.0315,"status":0,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2026-08-03。","afterMarket":{"amount":7938,"volume":300,"close":26.46,"buyVolume":200,"sellVolume":0,"time":1785483237746,"indexStatus":"已收盘 07-31 15:30:00","preClose":25.86},"hkstockBrief":{"symbol":"09969","market":"HK","secType":"STK","nameCN":"诺诚健华","latestPrice":13.64,"timestamp":1785485321008,"preClose":13.49,"halted":0,"volume":4668000,"delay":0,"premium":"-55.60"},"floatMarketCap":7219000000},"requestUrl":"/m/hq/s/688428/","defaultTab":"news","newsList":[{"id":"2655824162","title":"7月30日诺诚健华跌5.72%，富国精准医疗混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2655824162","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2655824162?lang=zh_cn&edition=full","pubTime":"2026-07-30 16:42","pubTimestamp":1785400974,"startTime":"0","endTime":"0","summary":"证券之星消息，7月30日诺诚健华跌5.72%，收盘报25.86元，换手率4.32%，成交量11.8万手，成交额3.11亿元。根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共36家，其中持有数量最多的公募基金为富国基金的富国精准医疗混合A。富国精准医疗混合A目前规模为28.98亿元，最新净值3.3851，较上一交易日下跌1.02%，近一年下跌6.77%。富国精准医疗混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026073000026016.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","BK1574","BK0239","09969","688428"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119065472","title":"诺诚健华Tyk2抑制剂Fadeucravacitinib (Icp-488)在银屑病三期研究中达成主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=1119065472","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1119065472?lang=zh_cn&edition=full","pubTime":"2026-07-27 18:57","pubTimestamp":1785149844,"startTime":"0","endTime":"0","summary":"诺诚健华（Innocare Pharma Limited）的Tyk2抑制剂Fadeucravacitinib（代号Icp-488），在一项针对银屑病的三期临床试验中，成功达到了主要终点。这一结果标志着该候选药物在治疗自身免疫性疾病领域取得了关键性进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688428","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1114086045","title":"诺诚健华：Fadeucravacitinib (Icp-488) 治疗中重度斑块状银屑病 III 期注册试验成功达成主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=1114086045","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1114086045?lang=zh_cn&edition=full","pubTime":"2026-07-27 17:41","pubTimestamp":1785145284,"startTime":"0","endTime":"0","summary":"诺诚健华宣布，其自主研发的Fadeucravacitinib（Icp-488）在中重度斑块状银屑病患者的III期注册临床试验中，成功达到了主要终点。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688428","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654169740","title":"诺诚健华：ICP-488治疗银屑病III期试验达主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2654169740","media":"南方财经网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2654169740?lang=zh_cn&edition=full","pubTime":"2026-07-27 17:34","pubTimestamp":1785144840,"startTime":"0","endTime":"0","summary":"南财智讯7月27日电，诺诚健华（09969.HK）发布自愿公告，公司自主研发的TYK2变构抑制剂fadeucravacinib（ICP-488）用于治疗中重度斑块状银屑病的III期注册性临床试验成功达到主要终点，统计学显著且具临床意义，并同步达成多项次要终点。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607273822201140.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607273822201140.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","BK1574","BK4134","688428","09969","III","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653737746","title":"BMS的留白，诺诚健华的窗口","url":"https://stock-news.laohu8.com/highlight/detail?id=2653737746","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653737746?lang=zh_cn&edition=full","pubTime":"2026-07-22 15:36","pubTimestamp":1784705799,"startTime":"0","endTime":"0","summary":"更关键的产业意义在于：全球第一个用于特应性皮炎的TYK2抑制剂，大概率将出自诺诚健华之手。BMS的留白，诺诚健华的窗口全球TYK2先驱BMS的Deucravacitinib选择了另一条路：聚焦银屑病、银屑病关节炎、系统性红斑狼疮，未大规模开展针对特应性皮炎的关键注册临床。BMS这一战略留白，恰好让出了一道窄门。在特应性皮炎这条BMS放弃的赛道上，诺诚健华的坚持正在得到回报。全球权益的含金量一个值得注意的事实是，诺诚健华至今仍持有ICP-332的全部全球权益。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1784604125251670229","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["09969","BK1574","BK1161","688428","BMS","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652371542","title":"每周股票复盘：诺诚健华（688428）Soficitinib治疗特应性皮炎Ⅲ期达主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2652371542","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2652371542?lang=zh_cn&edition=full","pubTime":"2026-07-19 01:32","pubTimestamp":1784395931,"startTime":"0","endTime":"0","summary":"截至2026年7月17日收盘，诺诚健华报收于26.52元，较上周的29.78元下跌10.95%。本周关注点公司公告汇总：Soficitinib治疗中重度特应性皮炎Ⅲ期注册性临床试验达到主要终点。公司公告汇总诺诚健华自主研发的新一代高选择性口服TYK2抑制剂soficitinib治疗成人中重度特应性皮炎的III期注册性临床试验达到主要终点，疗效在统计学上高度显著，并具临床意义，多个次要终点也达成。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071900000264.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688428","BK0239","BK1161","09969","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652209405","title":"7月17日诺诚健华跌9.21%，富国精准医疗混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2652209405","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2652209405?lang=zh_cn&edition=full","pubTime":"2026-07-17 16:29","pubTimestamp":1784276985,"startTime":"0","endTime":"0","summary":"证券之星消息，7月17日诺诚健华跌9.21%，收盘报26.52元，换手率8.86%，成交量24.17万手，成交额6.64亿元。根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共28家，其中持有数量最多的公募基金为富国基金的富国精准医疗混合A。富国精准医疗混合A目前规模为31.86亿元，最新净值3.7269，较上一交易日上涨0.34%，近一年上涨10.42%。富国精准医疗混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071700030025.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688428","BK0239","09969","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1122082851","title":"诺诚健华-索法西替尼二期试验展现良好安全性，未出现新的安全信号","url":"https://stock-news.laohu8.com/highlight/detail?id=1122082851","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1122082851?lang=zh_cn&edition=full","pubTime":"2026-07-16 21:11","pubTimestamp":1784207485,"startTime":"0","endTime":"0","summary":"诺诚健华旗下的候选药物索法西替尼，在二期临床试验中展现出良好的安全性特征，研究过程中未观察到新的安全信号。这一积极数据为这款在研药物的后续开发提供了重要支持。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","688428"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128065417","title":"诺诚健华旗下Soficitinib在II期试验中较安慰剂展现统计学显著改善","url":"https://stock-news.laohu8.com/highlight/detail?id=1128065417","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1128065417?lang=zh_cn&edition=full","pubTime":"2026-07-16 21:04","pubTimestamp":1784207075,"startTime":"0","endTime":"0","summary":"诺诚健华（Innocare Pharma）宣布，其在研药物Soficitinib于一项II期临床试验中，与安慰剂相比，取得了统计学上显著的改善效果。该结果标志着该候选药物的研发取得了积极进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688428","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1129132601","title":"诺诚健华TYK2抑制剂索法西替尼治疗白癜风II期研究达主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=1129132601","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1129132601?lang=zh_cn&edition=full","pubTime":"2026-07-16 21:01","pubTimestamp":1784206873,"startTime":"0","endTime":"0","summary":"诺诚健华宣布，其TYK2抑制剂索法西替尼在针对白癜风患者的II期临床研究中，达到了预设的主要终点。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","688428"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651417153","title":"诺诚健华(688428.SH)：Soficitinib(ICP-332)治疗非节段型白癜风Ⅱ期研究达到主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2651417153","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651417153?lang=zh_cn&edition=full","pubTime":"2026-07-16 16:42","pubTimestamp":1784191344,"startTime":"0","endTime":"0","summary":"智通财经APP讯，诺诚健华 发布公告，公司自主研发的新一代高选择性口服酪氨酸激酶2抑制剂soficitinib用于治疗非节段型白癜风患者的II/III期适应性临床研究中，II期阶段成功达到主要终点，并取得积极顶线结果。Soficitinib是公司自主研发的新一代高选择性口服TYK2抑制剂。TYK2属于Janus激酶家族成员，在白细胞介素-12/IL-23家族细胞因子受体及I型干扰素受体下游信号传导过程中发挥重要作用。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1468424.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688428","BK1161","BK0239","09969","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651469258","title":"诺诚健华（688428）披露2023年人民币股份激励计划归属结果，7月15日股价下跌2.18%","url":"https://stock-news.laohu8.com/highlight/detail?id=2651469258","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651469258?lang=zh_cn&edition=full","pubTime":"2026-07-15 22:07","pubTimestamp":1784124436,"startTime":"0","endTime":"0","summary":"截至2026年7月15日收盘，诺诚健华报收于29.63元，较前一交易日下跌2.18%，最新总市值为524.19亿元。该股当日开盘30.31元，最高31.9元，最低29.12元，成交额达7.09亿元，换手率为8.46%。近日，诺诚健华医药有限公司根据2023年人民币股份激励计划的归属结果，向2名董事、1名高级管理人员及132名激励对象发行新人民币股份，合计1,644,750股，每股发行价为人民币6.95元。本次发行后，公司已发行股份总数由2026年6月30日的1,764,576,252股增至1,766,221,002股。此次变动未导致库存股份变动。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071500044610.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","688428","BK1161","UCmain","09969","CNHmain","CYB","MUCmain","MCNHmain","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1124883174","title":"诺诚健华-奥布替尼达到统计学显著主要终点及多个次要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=1124883174","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1124883174?lang=zh_cn&edition=full","pubTime":"2026-07-15 19:55","pubTimestamp":1784116513,"startTime":"0","endTime":"0","summary":"诺诚健华宣布，其创新药物奥布替尼在临床试验中成功达到预设的统计学显著主要终点，并同时达成了多个关键的次要终点。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688428","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1140913795","title":"诺诚健华宣布TYK2抑制剂Soficitinib治疗特应性皮炎III期研究达到主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=1140913795","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1140913795?lang=zh_cn&edition=full","pubTime":"2026-07-15 19:55","pubTimestamp":1784116512,"startTime":"0","endTime":"0","summary":"诺诚健华公布其TYK2抑制剂Soficitinib用于治疗特应性皮炎的III期临床研究结果，该研究成功达到了预设的主要终点。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688428","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651452404","title":"诺诚健华(09969)：soficitinib (ICP-332)治疗中重度特应性皮炎的 III期注册性试验成功达到其主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2651452404","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651452404?lang=zh_cn&edition=full","pubTime":"2026-07-15 18:58","pubTimestamp":1784113097,"startTime":"0","endTime":"0","summary":"智通财经APP讯，诺诚健华 公布，公司自主研发的新一代口服酪氨酸激酶2抑制剂soficitinib ，用于治疗中重度特应性皮炎患者的III期注册性临床试验成功达到其主要终点。研究结果显示，soficitinib 达到主要终点，在统计学上具有显著性，并取得具有临床意义的改善。公司将继续完成正在进行中的III期研究，包括长期安全性随访，并计划于研究完成后推进soficitinib 用于治疗中重度特应性皮炎的注册申报工作。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1467988.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09969","III","688428","BK1574","BK0239","BK1161","BK4134"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651452187","title":"诺诚健华：Soficitinib治疗中重度特应性皮炎Ⅲ期临床试验达主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2651452187","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651452187?lang=zh_cn&edition=full","pubTime":"2026-07-15 18:50","pubTimestamp":1784112604,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["688428","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650815490","title":"每周股票复盘：诺诚健华（688428）科创板股份归属上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2650815490","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2650815490?lang=zh_cn&edition=full","pubTime":"2026-07-12 02:32","pubTimestamp":1783794729,"startTime":"0","endTime":"0","summary":"截至2026年7月10日收盘，诺诚健华报收于29.78元，较上周的30.18元下跌1.33%。本周关注点来自公司公告汇总：诺诚健华完成2023年科创板限制性股票激励计划部分归属，新增股份2,044,750股于2026年7月15日上市。诺诚健华医药有限公司完成2023年科创板限制性股票激励计划首次授予部分第三个归属期及预留授予部分第二个归属期的股份登记工作。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071200000813.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09969","688428","BK1161","BK1574","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650010135","title":"诺诚健华（688428）披露2023年科创板限制性股票激励计划归属结果暨股份上市公告，7月10日股价上涨2.34%","url":"https://stock-news.laohu8.com/highlight/detail?id=2650010135","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2650010135?lang=zh_cn&edition=full","pubTime":"2026-07-10 22:29","pubTimestamp":1783693755,"startTime":"0","endTime":"0","summary":"截至2026年7月10日收盘，诺诚健华报收于29.78元，较前一交易日上涨2.34%，最新总市值为526.23亿元。公告显示，公司已完成2023年科创板限制性股票激励计划首次授予部分第三个归属期及预留授予部分第二个归属期的股份登记工作。本次归属合计134人，归属股票数量为2,044,750股，来源为公司向激励对象定向发行人民币普通股股票。上市流通日为2026年7月15日。安永华明会计师事务所已完成验资，公司已收到激励对象缴纳的合计人民币14,211,012.50元出资款。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071000044628.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","09969","688428","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180945737","title":"港股创新药概念股盘中拉升，荣昌生物、诺诚健华涨超5%","url":"https://stock-news.laohu8.com/highlight/detail?id=1180945737","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1180945737?lang=zh_cn&edition=full","pubTime":"2026-07-10 10:01","pubTimestamp":1783648919,"startTime":"0","endTime":"0","summary":"7月10日，港股创新药概念股盘中拉升，$荣昌生物(09995)$、$诺诚健华(09969)$涨超5%，$药明康德(02359)$、$药明生物(02269)$、$亚盛医药(06855)$、$乐普生物(02157)$涨超4%，$恒瑞医药(01276)$涨超3%。","market":"hk","thumbnail":"https://static.tigerbbs.com/a5d11890cd6ccd454a56d86737fd3353","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/a5d11890cd6ccd454a56d86737fd3353"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09969","LU1064130708.USD","BK0239","KCAI","159992","IBBQ","BK4588","VXUS","BK1161","688428","06978","BK1583","LU1064131003.USD","688331","BK1574","BK4585","LU1969619763.USD","LU2328871848.SGD","LU2488822045.USD","MEDX","LU2148510915.USD","09995"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649985891","title":"诺诚健华：截止到2026年6月30日公司A股股东户数约为2万户","url":"https://stock-news.laohu8.com/highlight/detail?id=2649985891","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649985891?lang=zh_cn&edition=full","pubTime":"2026-07-07 17:06","pubTimestamp":1783415169,"startTime":"0","endTime":"0","summary":"证券之星消息，诺诚健华(688428)07月07日在投资者关系平台上答复投资者关心的问题。投资者提问：请问公司截止6月30日的股东人数诺诚健华回复：尊敬的投资者，您好！截止到2026年6月30日公司A股股东户数约为2万户。感谢您的关注！本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。责任编辑：刘浩然","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070700028459.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","BK0239","159982","399300","688428","BK1574","09969"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1785537459313,"stockEarnings":[{"period":"1week","weight":-0.0441},{"period":"1month","weight":-0.1052},{"period":"3month","weight":-0.0071},{"period":"6month","weight":0.2364},{"period":"1year","weight":-0.1256},{"period":"ytd","weight":0.2895}],"compareEarnings":[{"period":"1week","weight":0.0047},{"period":"1month","weight":-0.0681},{"period":"3month","weight":-0.0681},{"period":"6month","weight":-0.0694},{"period":"1year","weight":0.0725},{"period":"ytd","weight":-0.0344}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"诺诚健华医药有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"20000人(较上一季度增加0.00%)","perCapita":"13641股","listingDate":"2022-09-21","address":"Ogier Global (Cayman) Limited, 89 Nexus Way, Camana Bay, Grand Cayman, KY1-9009, Cayman Islands","registeredCapital":"0万元","survey":" 诺诚健华医药有限公司的主营业务是创新药的研发、生产及商业化。公司的主要产品是奥布替尼。","listedPrice":11.03},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"诺诚健华(688428)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供诺诚健华(688428)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"诺诚健华,688428,诺诚健华股票,诺诚健华股票老虎,诺诚健华股票老虎国际,诺诚健华行情,诺诚健华股票行情,诺诚健华股价,诺诚健华股市,诺诚健华股票价格,诺诚健华股票交易,诺诚健华股票购买,诺诚健华股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"诺诚健华(688428)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供诺诚健华(688428)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}